Table 4.

New Cancers following BRAF/MEK Inhibitor Therapy

New Cancer Diagnosis Following BRAF/MEK Inhibitor Therapy (n=24)	n (% of those with new cancer diagnoses)
Duration from Treatment Start to New Cancer Diagnosis (median; months)	51.1
Stage
Localized	19 (79.2)
Regional	3 (12.5)
Metastatic	1 (4.2)
Unknown	1 (4.2)
Type
Anal SCC	1 (4.2)
Breast	1 (4.2)
Non-melanoma skin cancer	17 (70.8)
Melanoma (new primary)	2 (8.3)
Lymphoma	1 (4.2)
Esophageal adenocarcinoma	1 (4.2)
Head and neck cancer*	2 (8.3)
Lung, adenocarcinoma	1 (4.2)
Prostate	1 (4.2)

^*Tonsillar (n=1), tongue (n=1)